Targeted Intranasal Mupirocin To Prevent Colonization and Infection by Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Soldiers: a Cluster Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging pathogen that primarily manifests as uncomplicated skin and soft tissue infections. We conducted a cluster randomized, double-blind, placebo-controlled trial to determine whether targeted intranasal mupirocin therapy in CA-MRSA-colonized soldiers could prevent infection in the treated individual and prevent new colonization and infection within their study groups. We screened 3,447 soldiers comprising 14 training classes for CA-MRSA colonization from January to December 2005. Each training class was randomized to either the mupirocin or placebo study group, and the participants identified as CA-MRSA colonized were treated with either mupirocin or placebo. All participants underwent repeat screening after 8 to 10 weeks and were monitored for 16 weeks for development of infection. Of 3,447 participants screened, 134 (3.9%) were initially colonized with CA-MRSA. Five of 65 (7.7%; 95% confidence interval [95% CI], 4.0% to 11.4%) placebo-treated participants and 7 of 66 (10.6%; 95% CI, 7.9% to 13.3%) mupirocin-treated participants developed infections; the difference in the infection rate of the placebo- and mupirocin-treated groups was −2.9% (95% CI, −7.5% to 1.7%). Of those not initially colonized with CA-MRSA, 63 of 1,459 (4.3%; 95% CI, 2.7% to 5.9%) of the placebo group and 56 of 1,607 (3.5%; 95% CI, 2.6% to 5.2%) of the mupirocin group developed infections; the difference in the infection rate of the placebo and mupirocin groups was 0.8% (95% CI, −1.0% to 2.7%). Of 3,447 participants, 3,066 (89%) were available for the second sampling and completed follow-up. New CA-MRSA colonization occurred in 24 of 1,459 (1.6%; 95% CI, 0.05% to 2.8%) of the placebo group participants and 23 of 1,607 (1.4%; 95% CI, 0.05% to 2.3%) of the mupirocin group participants; the difference in the infection rate of the placebo and mupirocin groups was 0.2% (95% CI, −1.3% to 1.7%). Despite CA-MRSA eradication in colonized participants, this study showed no decrease in infections in either the mupirocin-treated individuals or within their study group. Furthermore, CA-MRSA eradication did not prevent new colonization within the study group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of nasal carriage in Staphylococcus aureus infections
Wertheim, H. F., Melles, D. C., Vos, M. C., van Leeuwen, W., van Belkum, A., Verbrugh, H. A., & Nouwen, J. L. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70295-4 · Cited by 2,685 · cited 4×
“infection with the endogenous strain (12, 28, 45, 47, 49, 51, 52).”
BackgroundInfluentialNasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks
Kluytmans, J., van Belkum, A., & Verbrugh, H. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.3.505 · Cited by 2,595
Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department
Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., & Talan, D. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055356 · Cited by 2,285
Nasal Carriage as a Source of Staphylococcus aureus Bacteremia
von Eiff, C., Becker, K., Machka, K., Stammer, H., & Peters, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440102 · Cited by 1,984
Methicillin-Resistant Staphylococcus aureus Disease in Three Communities
Fridkin, S. K., Hageman, J. C., Morrison, M., Sanza, L. T., Como-Sabetti, K., Jernigan, J. A., Harriman, K., Harrison, L. H., Lynfield, R., & Farley, M. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043252 · Cited by 1,493
Miller, L. G., Perdreau-Remington, F., Rieg, G., Mehdi, S., Perlroth, J., Bayer, A. S., Tang, A. W., Phung, T. O., & Spellberg, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042683 · Cited by 1,053 · cited 1×
“The majority of CA-MRSA infections manifest as uncomplicated skin and soft tissue infections; however, severe infections resulting in considerable morbidity and mortality have been reported (4, 19, 20, 22, 34, 36 ).”
BackgroundKing, M. D., Humphrey, B. J., Wang, Y. F., Kourbatova, E. V., Ray, S. M., & Blumberg, H. M. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00005 · Cited by 776 · cited 1×
“Evidence of this has been demonstrated in recent investigations that showed that PFT USA 300 is the principal cause of suppurative soft tissue infections in some urban areas and university-affiliated emergency departments (27, 38).”
ResultPrevalence of Staphylococcus aureus Nasal Colonization in the United States, 2001–2002
Kuehnert, M. J., Kruszon‐Moran, D., Hill, H. A., McQuillan, G., McAllister, S. K., Fosheim, G., McDougal, L. K., Chaitram, J., Jensen, B., Fridkin, S. K., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/499632 · Cited by 659
Groom, A. V. (2001) · JAMA · doi:10.1001/jama.286.10.1201 · Cited by 360
Lindenmayer, J. M., Schoenfeld, S., O'Grady, R., & Carney, J. K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.8.895 · Cited by 298 · cited 1×
“Indeed, some groups, among whom soldiers are included, appear to be at increased risk (1, 3, 5, 6, 23, 33 , 40, 53).”
Background
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Targeted versus universal decolonization to prevent ICU infection
Huang, S. S., Septimus, E., Kleinman, K., Moody, J., Hickok, J., Avery, T. R., Lankiewicz, J., Gombosev, A., Terpstra, L., Hartford, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207290 · Cited by 795
Shallcross, L. J., Fragaszy, E., Johnson, A. M., & Hayward, A. C. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70238-4 · Cited by 463
Metadata
- Authors
- Ellis, M. W., Griffith, M. E., Dooley, D. P., McLean, J. C., Jorgensen, J. H., Patterson, J. E., Davis, K. A., Hawley, J. S., Regules, J. A., Rivard, R. G., Gray, P. J., Ceremuga, J. M., DeJoseph, M. A., & Hospenthal, D. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-10
- Volume
- 51
- Issue
- 10
- Pages
- 3591-3598
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2116218322
- Cited by
- 129
- References
- 11
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Intranasal Mupirocin To Prevent Colonization and Infection by Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Soldiers: a Cluster Randomized Controlled Trial. https://app.cochat.ai/papers/10.1128/aac.01086-06
- The paper
- Ellis, M. W., Griffith, M. E., Dooley, D. P., McLean, J. C., Jorgensen, J. H., Patterson, J. E., Davis, K. A., Hawley, J. S., Regules, J. A., Rivard, R. G., Gray, P. J., Ceremuga, J. M., DeJoseph, M. A., & Hospenthal, D. R. (2007). Targeted Intranasal Mupirocin To Prevent Colonization and Infection by Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Soldiers: a Cluster Randomized Controlled Trial. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01086-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.